Media ReleasesImmutep

View All Immutep News

Immutep Announces European Patent Secured for Eftilagimod Alpha in Combination with Therapeutic Antibodies for Treating Cancer

SYDNEY, AUSTRALIA – November 29, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of patent number 2601961 entitled “Compositions comprising LAG-3 and therapeutic antibodies and their uses in treating cancer” by the European Patent Office.

This European patent was filed as a divisional application, and follows the grant of the parent application and another divisional application in Europe in 2013 and 2017, respectively.

For further information please download PDF attached:
Download this document